Liminatus Pharma LIMN 深 沪
等待开盘 10-15 09:30:00 美东时间
3.3315
-0.078
-2.30%
华盛通- 最 高3.55
- 今 开3.43
- 成交量 1.61万股
- 最 低 3.32
- 昨 收 3.41
- 总市值 447.49万
- 52周最高 141.50
- 市盈率 静 --
- 换手率 1.20%
- 52周最低 3.29
- 委 比 0.00%
- 总股本 134.32万
- 历史最高 1683.00
- 量 比 1.22
- 振 幅 6.74%
- 历史最低 3.32
- 每 手 1
- 风险率 21.68%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Liminatus Pharma Regains Nasdaq Compliance After Reverse Split
Liminatus Pharma ( ($LIMN) ) has shared an announcement. On January 15, 2026, L...
09-29 21:59
Liminatus Pharma regains Nasdaq compliance
Liminatus Pharma (LIMN) announced on Tuesday that the company has regained compliance with Nasdaq’s minimum bid price rule. As previously disclosed, on January 15, 2026, the company received a notice ...
09-29 21:36
Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule
Liminatus Pharma, Inc. has regained compliance with Nasdaq's minimum bid price rule after its stock price remained above $1.00 for 13 consecutive trading days. The company had previously been warned for failing to meet the $1.00 bid price requirement and was transferred to the Nasdaq Capital Market. Following a 1-for-50 reverse stock split, Liminatus successfully demonstrated compliance, closing the matter. The company, focused on immuno-oncology...
09-29 13:00
Liminatus Pharma Engages Synex Consulting To Support Clinical Development Of IBC101, CD19xCD22 Bivalent CAR-T Cell Therapy Candidate
Liminatus Pharma, Inc. (NASDAQ:LIMN) ("Liminatus" or the "Company"), a biotechnology company developing innovative cancer therapies, today announced that it has engaged Synex Consulting Ltd. ("Synex"), a Korea-based full-service contract research organization ("CRO"), to support the clinical develop...
08-24 20:01
Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy
Liminatus Pharma has engaged Synex Consulting to support the clinical development of IBC101, a CD19xCD22 bivalent CAR-T therapy for relapsed or refractory B-cell malignancies, in South Korea. IBC101 has received MFDS authorization for a Phase 1/2a study in DLBCL patients, with Synex providing milestone-based clinical services. The collaboration aims to advance IBC101 toward clinical execution, leveraging Synex's local expertise. IBC101 targets CD...
08-24 12:00
Liminatus Pharma shares are trading higher after the company announced its stock transfer to the Nasdaq Capital Market and an extension to meet minimum bid price compliance.
Liminatus Pharma shares are trading higher after the company announced its stock transfer to the Nasdaq Capital Market and an extension to meet minimum bid price compliance.
08-14 02:58
Liminatus Pharma Shareholders Approve Reverse Stock Split Plan
An announcement from Liminatus Pharma ( ($LIMN) ) is now available. On August 3...
08-05 05:37
11 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Chemomab Therapeutics (NASDAQ:CMMB) stock increased by 33.8% to $2.27 during Thursday's regular session. The market value of their outstanding shares is at $12.2 million. Liminatus Pharma (NASDAQ:LIMN) shares rose 26.04% to $0.14. The market value of their outstanding shares is at $5.8 milli...
07-03 01:05
Liminatus Pharma Amends Proposed $320M Merger Deal With InnocsAI As Closing Now Anticipated Before Shareholder Approval On July 2
Liminatus Pharma, Inc. (Nasdaq: LIMN) ("Liminatus" or the "Company"), a biotechnology company developing innovative cancer therapies, today announced that it has amended and restated the previously announced definitive merger agreement with InnocsAI LLC ("InnocsAI"), an oncology biotechnology compan...
07-01 04:32
